Printer Friendly

CardioDynamics International's noninvasive hemodynamic technology is boosted by recent study which questions safety of invasive right heart catheter.

SAN DIEGO--(BUSINESS WIRE)--Sept. 18, 1996-- CardioDynamics International Corp. (OTC:CRDY) announced that the article published in today's Journal of the American Medical Association (JAMA), which questions the safety of invasive right heart catheters, has significance for CardioDynamics' noninvasive technology and their BioZ System hemodynamic monitor.

The JAMA article highlights the costs and the risks of complications and death associated with the invasive technology.

Dr. Nicholas Diaco, director of the Cardiac Catheterization Laboratory at St. John's Hospital in Santa Monica, Calif. and a CardioDynamics' board member, said, "the article confirms the numerous risks associated with the invasive procedure and underscores the need for noninvasive alternatives."

Dr. William Maguire, M.D., Ph.D, a critical care specialist at Grossmont Sharp Hospital in San Diego, added that "the problems lie with the right heart catheter." He also stated that "the need for the hemodynamic data exists and that this study makes the pursuit of noninvasive technology, such as CardioDynamics' noninvasive thoracic electrical bioimpedance (TEB), paramount." Dr. Maguire is a member of CardioDynamics' medical advisory board.

CardioDynamics' proprietary noninvasive technology allows for assessment and trending of parameters similar to those provided by the invasive right heart catheters, such as the popular Swan-Ganz catheter.

CardioDynamics has recently filed a 510(k) on its BioZ System which is currently being utilized in clinical studies at Brigham and Women's Hospital, Scripps Clinic and Research Foundation, University of California at San Diego, University of Washington and Mayo Clinic (Rochester). The studies will include analysis of patient outcomes and cost efficiencies realized through the use of the company's noninvasive hemodynamic monitors.

A June 15, 1996, article published in the American Journal of Cardiology comparing CardioDynamics' noninvasive technology with invasive procedures, including the right heart catheter, concluded that there were no significant differences in the stroke volume and cardiac output hemodynamic data obtained by TEB and right heart catheters.

The article stated that TEB is a noninvasive, simple, accurate and reproducible technique. An additional and important advantage of CardioDynamics' noninvasive technology is its substantially lower cost, given that the invasive right heart catheter is associated with approximately $2 billion in medical costs annually in the United States.

CardioDynamics' new system, the BioZ, is a digital signal processor-based noninvasive hemodynamic monitoring system. With the BioZ System, the company expects to expand on its installed base of over 1500 hemodynamic monitors worldwide. The company estimates a potential market of $2 billion for its products.

CardioDynamics International Corp. is a San Diego, Calif.-based developer and marketer of noninvasive cardiac output monitoring systems which use its patented Thoracic Electrical Bioimpedance technology. For further information, contact: Richard E. Otto, chief executive officer or Rhonda F. Pederson, chief operating officer, at (800) 778-4825.

CONTACT: CardioDynamics International Corp.

Richard E. Otto or Rhonda F. Pederson

(800) 778-4825
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 18, 1996
Previous Article:Samsung Announces Industry's First Low-Cost USB Microcontroller with Integrated ROM; Supports 1.5 Mbps Bus Rates for Hot "Plug 'n Play" Mouse &...
Next Article:Med Advantage receives NCQA certification.

Related Articles
Cardiac Pathways Reports First Human Use of Arrhythmia Mapping System for Ischemic Ventricular Tachycardia; Improved Diagnostic Procedure a Critical...
Condition critical: is the right-heart catheter dangerous?
CardioDynamics Announces Initial Commercial Sales Of The BioZ System.
CardioDynamics - CDIC - Announces the BioZ Systems' Introduction at the 62nd Anniversary of the Japanese Circulatory Congress, Tokyo.
CardioDynamics International Corporation Announces European Launch of the at the 20th Congress of the European Society of Cardiology,...
CardioDynamics CDIC Awarded Government of Mexico Contract; Company also Reports Increasing Trend of Orders for Multiple BioZ Systems.
GE Marquette Medical Systems and CardioDynamics International Announce Strategic Alliance; GE Marquette Commits to Initial Purchase of...
CardioDynamics Announces Results of Two Significant BioZ Accuracy Studies at the CHEST 1999 Meeting, Chicago.
CardioDynamics - `CDIC' - Announces BioZ Study Demonstrating $1 Billion Potential Healthcare Savings.
Upper-extremity deep vein thrombosis. (Featured CME Topic: Upper-Extremity DVT).

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters